This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 1998 Dec;29(6):1010-4.

doi: 10.1016/s0168-8278(98)80133-5.

Combination therapy of chronic hepatitis C: an important step but not the final goal!

H Wedemeyer, W H Caselmann, M P Manns

PMID: 9875652
DOI: 10.1016/s0168-8278(98)80133-5

Editorial

Combination therapy of chronic hepatitis C: an important step but not the final goal!

H Wedemeyer et al. J Hepatol. 1998 Dec.

. 1998 Dec;29(6):1010-4.

doi: 10.1016/s0168-8278(98)80133-5.

Authors

H Wedemeyer, W H Caselmann, M P Manns

PMID: 9875652
DOI: 10.1016/s0168-8278(98)80133-5

No abstract available

PubMed Disclaimer

Similar articles

Double filtration plasmapheresis could induce a favorable immune response for chronic hepatitis C therapy.
Kondo Y, Ueno Y, Shimosegawa T. Kondo Y, et al. Ther Apher Dial. 2012 Oct;16(5):478-9. doi: 10.1111/j.1744-9987.2012.01113.x. Ther Apher Dial. 2012. PMID: 23046374 No abstract available.
I favor therapy for hepatitis C virus recurrence after transplantation.
Samuel D. Samuel D. Liver Transpl. 2002 Oct;8(10 Suppl 1):S55-8. doi: 10.1053/jlts.2002.35857. Liver Transpl. 2002. PMID: 12362300 No abstract available.
Efficacy of double filtration plasmapheresis with pegylated interferon/ribavirin therapy for intractable chronic hepatitis C patients and hepatitis C patients with combined liver cirrhosis by HBV, leading to early viral elimination.
Ohara T, Oteki T, Suzuki T, Suzuki M, Matsuzaki Y. Ohara T, et al. Hepatogastroenterology. 2011 Jan-Feb;58(105):133-6. Hepatogastroenterology. 2011. PMID: 21510300
Practical management of liver transplant recipients for hepatitis C.
Saab S, Busuttil RW. Saab S, et al. Minerva Chir. 2003 Aug;58(4):479-89. Minerva Chir. 2003. PMID: 14603160 Review.
[Ribavirin/interferon-alpha combination in treatment of chronic hepatitis C: what is the status today?].
Renner EL. Renner EL. Schweiz Med Wochenschr. 1999 Jan 12;129(1-2):8-10. Schweiz Med Wochenschr. 1999. PMID: 10065494 Review. German. No abstract available.

See all similar articles

Cited by

Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon.
Markland W, McQuaid TJ, Jain J, Kwong AD. Markland W, et al. Antimicrob Agents Chemother. 2000 Apr;44(4):859-66. doi: 10.1128/AAC.44.4.859-866.2000. Antimicrob Agents Chemother. 2000. PMID: 10722482 Free PMC article.
Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus.
Kwong AD, Kauffman RS, Hurter P, Mueller P. Kwong AD, et al. Nat Biotechnol. 2011 Nov 8;29(11):993-1003. doi: 10.1038/nbt.2020. Nat Biotechnol. 2011. PMID: 22068541
Design, delivery and efficacy testing of therapeutic nucleic acidsused to inhibit hepatitis C virus gene expression in vitro and in vivo.
Caselmann WH, Serwe M, Lehmann T, Ludwig J, Sproat BS, Engels JW. Caselmann WH, et al. World J Gastroenterol. 2000 Oct;6(5):626-629. doi: 10.3748/wjg.v6.i5.626. World J Gastroenterol. 2000. PMID: 11819663 Free PMC article. No abstract available.
Interleukin 6 and 12, alanine aminotransferase activity, and HCV viral load in children with chronic hepatitis C treated with interferon and ribavirin.
Kowala-Piaskowska A, Mozer-Lisewska I, Figlerowicz M, Machowska L, Słuzewski W. Kowala-Piaskowska A, et al. Inflammation. 2004 Dec;28(6):319-25. doi: 10.1007/s10753-004-6642-y. Inflammation. 2004. PMID: 16245074

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.